134 related articles for article (PubMed ID: 17924426)
1. High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. Aggregation kinetics.
Alford JR; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2008 Aug; 97(8):3005-21. PubMed ID: 17924426
[TBL] [Abstract][Full Text] [Related]
2. High concentration formulations of recombinant human interleukin-1 receptor antagonist: I. Physical characterization.
Alford JR; Kwok SC; Roberts JN; Wuttke DS; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2008 Aug; 97(8):3035-50. PubMed ID: 17973297
[TBL] [Abstract][Full Text] [Related]
3. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution.
Chang BS; Beauvais RM; Arakawa T; Narhi LO; Dong A; Aparisio DI; Carpenter JF
Biophys J; 1996 Dec; 71(6):3399-406. PubMed ID: 8968609
[TBL] [Abstract][Full Text] [Related]
4. Protein-protein interactions controlling interfacial aggregation of rhIL-1ra are not described by simple colloid models.
Sorret LL; DeWinter MA; Schwartz DK; Randolph TW
Protein Sci; 2018 Jul; 27(7):1191-1204. PubMed ID: 29388282
[TBL] [Abstract][Full Text] [Related]
5. Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist.
Chi EY; Kendrick BS; Carpenter JF; Randolph TW
J Pharm Sci; 2005 Dec; 94(12):2735-48. PubMed ID: 16258998
[TBL] [Abstract][Full Text] [Related]
6. Temperature dependence of benzyl alcohol- and 8-anilinonaphthalene-1-sulfonate-induced aggregation of recombinant human interleukin-1 receptor antagonist.
Roy S; Katayama D; Dong A; Kerwin BA; Randolph TW; Carpenter JF
Biochemistry; 2006 Mar; 45(12):3898-911. PubMed ID: 16548517
[TBL] [Abstract][Full Text] [Related]
7. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor.
Chi EY; Krishnan S; Kendrick BS; Chang BS; Carpenter JF; Randolph TW
Protein Sci; 2003 May; 12(5):903-13. PubMed ID: 12717013
[TBL] [Abstract][Full Text] [Related]
8. High-pressure studies of aggregation of recombinant human interleukin-1 receptor antagonist: thermodynamics, kinetics, and application to accelerated formulation studies.
Seefeldt MB; Kim YS; Tolley KP; Seely J; Carpenter JF; Randolph TW
Protein Sci; 2005 Sep; 14(9):2258-66. PubMed ID: 16081653
[TBL] [Abstract][Full Text] [Related]
9. Effect of benzyl alcohol on recombinant human interleukin-1 receptor antagonist structure and hydrogen-deuterium exchange.
Alford JR; Fowler AC; Wuttke DS; Kerwin BA; Latypov RF; Carpenter JF; Randolph TW
J Pharm Sci; 2011 Oct; 100(10):4215-24. PubMed ID: 21557223
[TBL] [Abstract][Full Text] [Related]
10. Oxidation of methionine residues in recombinant human interleukin-1 receptor antagonist: implications of conformational stability on protein oxidation kinetics.
Thirumangalathu R; Krishnan S; Bondarenko P; Speed-Ricci M; Randolph TW; Carpenter JF; Brems DN
Biochemistry; 2007 May; 46(21):6213-24. PubMed ID: 17480058
[TBL] [Abstract][Full Text] [Related]
11. Particle Formation and Aggregation of a Therapeutic Protein in Nanobubble Suspensions.
Snell JR; Zhou C; Carpenter JF; Randolph TW
J Pharm Sci; 2016 Oct; 105(10):3057-3063. PubMed ID: 27488901
[TBL] [Abstract][Full Text] [Related]
12. Measurement of the second osmotic virial coefficient for protein solutions exhibiting monomer-dimer equilibrium.
Alford JR; Kendrick BS; Carpenter JF; Randolph TW
Anal Biochem; 2008 Jun; 377(2):128-33. PubMed ID: 18395000
[TBL] [Abstract][Full Text] [Related]
13. Mechanism for benzyl alcohol-induced aggregation of recombinant human interleukin-1 receptor antagonist in aqueous solution.
Zhang Y; Roy S; Jones LS; Krishnan S; Kerwin BA; Chang BS; Manning MC; Randolph TW; Carpenter JF
J Pharm Sci; 2004 Dec; 93(12):3076-89. PubMed ID: 15514986
[TBL] [Abstract][Full Text] [Related]
14. Denaturant-dependent conformational changes in a beta-trefoil protein: global and residue-specific aspects of an equilibrium denaturation process.
Latypov RF; Liu D; Jacob J; Harvey TS; Bondarenko PV; Kleemann GR; Brems DN; Raibekas AA
Biochemistry; 2009 Nov; 48(46):10934-47. PubMed ID: 19839644
[TBL] [Abstract][Full Text] [Related]
15. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: role in restricted conformational mobility and compaction of native state.
Kendrick BS; Chang BS; Arakawa T; Peterson B; Randolph TW; Manning MC; Carpenter JF
Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11917-22. PubMed ID: 9342337
[TBL] [Abstract][Full Text] [Related]
16. Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations.
Roy S; Jung R; Kerwin BA; Randolph TW; Carpenter JF
J Pharm Sci; 2005 Feb; 94(2):382-96. PubMed ID: 15614819
[TBL] [Abstract][Full Text] [Related]
17. Multistep aggregation pathway of human interleukin-1 receptor antagonist: kinetic, structural, and morphological characterization.
Krishnan S; Raibekas AA
Biophys J; 2009 Jan; 96(1):199-208. PubMed ID: 19134476
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor.
Moore JM; Patapoff TW; Cromwell ME
Biochemistry; 1999 Oct; 38(42):13960-7. PubMed ID: 10529242
[TBL] [Abstract][Full Text] [Related]
19. Kinetic and thermodynamic analysis of thermal unfolding of recombinant erythropoietin.
Arakawa T; Philo JS; Kita Y
Biosci Biotechnol Biochem; 2001 Jun; 65(6):1321-7. PubMed ID: 11471731
[TBL] [Abstract][Full Text] [Related]
20. Thermodynamic studies of the core histones: pH and ionic strength effects on the stability of the (H3-H4)/(H3-H4)2 system.
Karantza V; Freire E; Moudrianakis EN
Biochemistry; 1996 Feb; 35(6):2037-46. PubMed ID: 8639689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
